InnoCare Pharma Limited (9969.HK)
HKSE · HKD · Healthcare · Biotechnology
HK$11.42 (-1.64%) as of
Key statistics
- Market cap
- 20.18B
- P/E (TTM)
- 19.03
- Forward P/E
- 54.00
- EPS (TTM)
- 0.600
- Dividend yield
- 0.00%
- 52-week range
- 9.650 – 16.200
- Revenue (TTM)
- 3.36B
- Profit margin
- 40.57%
- Analyst target
- HK$19.10
- Volume
- 8.30M
About InnoCare Pharma Limited
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. It also developing ICP-B02 to treat CD20+B-cell malignancies; ICP-B05 to treat hemato-oncology; ICP-248 to treat chronic lymphocytic leukemia; ICP-332 to treat atopic dermatitis; ICP-488 to treat psoriasis; ICP-538 to treat autoimmune diseases; zurletrectinib (ICP-723) to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-189 to treat non-small cell lung cancer; and ICP-B05 to treat solid tumor. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Beijing, China
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.